Reprogramming the Microbiome: Engineering Phage-Resistant LBPs for Durable Therapeutic Impact
- Demonstrate how CRISPR-enhanced bacterial strains resist phage attack to improve engraftment and therapeutic persistence
- Leverage virome analysis to uncover viral drivers of LBP failure across women’s health and gut indications
- Expand platform applications from vaginal microbiome to gut disorders, showcasing data from preclinical developments